Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour

État Nombre total Résumé
Négociations actives 34 Non liées à l’oncologie: 21
Liées à l’oncologie: 13
Négociations envisagées 25 Non liées à l’oncologie: 15
Liées à l’oncologie: 10
Négociations terminées 619 Avec lettre d’intention: 530
Sans entente: 89
Négociations qui n’ont pas eu lieu 97

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Tecartus Gilead Sciences Canada Inc. For treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Lapelga Apobiologix, a Division of Apotex Inc. To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Trurapi sanofi-aventis Canada Inc. • the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin) • continuous subcutaneous insulin infusion (CSII) in pump system
Livtencity Takeda Canada Inc. post-transplant cytomegalovirus (CMV) infection/disease
Ultomiris Alexion Pharma Canada Corp. Paroxysmal nocturnal hemoglobinuria (PNH)
Ultomiris Alexion Pharma GMBH Atypical hemolytic uremic syndrome
Opdivo BRISTOL-MYERS SQUIBB CANADA For the neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy
Dayvigo Eisai Limited Insomnia
Kimmtrak Medison Pharma Canada Inc. For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
"TBC" Teva Canada Inc. Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovas

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Lorbrena Pfizer Canada ULC for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Xpovio Forus Therapeutics Inc. For the treatment of adult patients, in combination with bortezomib (V) and dexamethasone (d), with multiple myeloma (MM) who have received at least one prior therapy.
Qinlock Medison Pharma Canada Inc. For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib
Keytruda Merck Canada Inc. in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum
Keytruda Merck Canada Inc. in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC
Byooviz Biogen Canada Inc. Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovas
Lenvima Eisai Limited In combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC)
Lenvima Eisai Limited In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based
Jakavi Novartis Pharmaceuticals Canada Inc. acute graft-versus-host disease
Jakavi Novartis Pharmaceuticals Canada Inc. chronic graft-versus-host disease

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Wakix Paladin Labs Inc. For the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines